Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)‘s stock had its “overweight” rating reissued by Piper Jaffray Companies in a research note issued on Wednesday. They presently have a $30.00 price target on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price objective would suggest a potential upside of 40.85% from the company’s previous close.

Other equities research analysts have also recently issued reports about the stock. Noble Financial restated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, August 9th. Cowen and Company set a $45.00 price target on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Mizuho restated a “buy” rating and set a $26.00 price target on shares of Adamas Pharmaceuticals in a report on Tuesday, June 6th. Needham & Company LLC restated a “buy” rating and set a $38.00 price target on shares of Adamas Pharmaceuticals in a report on Sunday. Finally, Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $36.67.

Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) traded up 0.4113% during mid-day trading on Wednesday, reaching $21.3876. The company had a trading volume of 685,564 shares. The company’s market capitalization is $481.52 million. Adamas Pharmaceuticals has a 52-week low of $12.10 and a 52-week high of $23.84. The company’s 50-day moving average price is $18.21 and its 200-day moving average price is $17.22.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.81) by ($0.12). Adamas Pharmaceuticals had a negative net margin of 10,499.65% and a negative return on equity of 52.91%. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million. During the same quarter last year, the company earned ($0.78) earnings per share. The firm’s revenue was down 90.9% on a year-over-year basis. On average, analysts forecast that Adamas Pharmaceuticals will post ($3.75) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Adamas Pharmaceuticals, Inc. (ADMS) Receives “Overweight” Rating from Piper Jaffray Companies” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/20/adamas-pharmaceuticals-inc-adms-receives-overweight-rating-from-piper-jaffray-companies.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADMS. Tower Research Capital LLC TRC bought a new stake in shares of Adamas Pharmaceuticals in the second quarter valued at about $109,000. American International Group Inc. lifted its stake in shares of Adamas Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock valued at $180,000 after buying an additional 682 shares during the period. Virtu KCG Holdings LLC bought a new stake in shares of Adamas Pharmaceuticals in the second quarter valued at about $184,000. Wells Fargo & Company MN lifted its stake in shares of Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock valued at $266,000 after buying an additional 3,358 shares during the period. Finally, Trexquant Investment LP bought a new stake in shares of Adamas Pharmaceuticals in the first quarter valued at about $287,000. Institutional investors and hedge funds own 69.24% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.